









市场行情
/
股票
/
nasdaq-sgmo
/

Sangamo Therapeutics Inc

SGMO

0.460USD

+0.014+3.09%

收盘 12/22, 16:00（美东）报价延迟15分钟

148.19M总市值

亏损市盈率 TTM



Sangamo Therapeutics Inc

0.460

+0.014+3.09%

概览公司财务分析

概览

公司

财务

分析

关于 Sangamo Therapeutics Inc 公司

Sangamo Therapeutics, Inc. is a genomic medicine company. The Company’s zinc finger (ZF) epigenetic regulators are ideally suited to potentially address neurological disorders and its capsid engineering platform has demonstrated the ability to expand delivery beyond available intrathecal delivery capsids, including in the central nervous system (CNS), in preclinical studies. Zinc finger technologies are derived from naturally occurring human proteins. They are composed of a DNA-binding domain, which binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) based on therapeutic needs. Its pipeline includes Chronic Neuropathic Pain - ST-503 and Isaralgagene civaparvovec (ST-920). ST-503 is an investigational epigenetic regulator for the treatment of intractable pain due to iSFN, a type of chronic neuropathic pain. ST-920 is a wholly owned gene therapy product candidate for the treatment of Fabry disease.

Sangamo Therapeutics Inc简介



公司代码SGMO

公司名称Sangamo Therapeutics Inc

上市日期Apr 06, 2000

CEOMacrae (Alexander D)

员工数量183

证券类型Ordinary Share

年结日Apr 06

公司地址501 Canal Blvd.

城市RICHMOND

上市交易所NASDAQ OMX - NASDAQ BASIC

国家United States of America

邮编94084

电话15109706000

网址https://www.sangamo.com/

公司代码SGMO

上市日期Apr 06, 2000

CEOMacrae (Alexander D)

Sangamo Therapeutics Inc公司高管



名称

名称/职务

职务

持股

持股变动

Mr. Scott B. Willoughby

Chief Legal Officer & Corporate Secretary

302.87K

-0.67%

Dr. Gregory Davis, Ph.D.

Head of Research & Technology

197.63K

-0.36%

Ms. Margaret A. Horn, J.D.

Independent Director

76.40K

+48.64%

Dr. Courtney Beers, Ph.D.

Independent Director

76.40K

+48.64%

Dr. Karen Lesley Smith, M.D., Ph.D.

Independent Director

Dr. John H. Markels, Ph.D.

Independent Director

Ms. Louise Wilkie

Investor Relations

Ms. H. Stewart Parker

Independent Chairman of the Board

Ms. Nathalie Dubois- Stringfellow, Ph.D.

Chief Development Officer

Mr. Robert F. Carey

Independent Director

名称

名称/职务

职务

持股

持股变动

Mr. Scott B. Willoughby

Chief Legal Officer & Corporate Secretary

302.87K

-0.67%

Dr. Gregory Davis, Ph.D.

Head of Research & Technology

197.63K

-0.36%

Ms. Margaret A. Horn, J.D.

Independent Director

76.40K

+48.64%

Dr. Courtney Beers, Ph.D.

Independent Director

76.40K

+48.64%

Dr. Karen Lesley Smith, M.D., Ph.D.

Independent Director

Dr. John H. Markels, Ph.D.

Independent Director

收入明细

FY2024

FY2023

由于公司未披露，未能获取相关数据

地区USD

名称

营收

占比

United States

57.80M

0.00%

业务

地区

由于公司未披露，未能获取相关数据

股东统计

更新时间: 11月21日周五

持股股东

股东类型

持股股东

占比

The Vanguard Group, Inc.

3.45%

Renaissance Technologies LLC

3.03%

Two Sigma Investments, LP

1.38%

BlackRock Institutional Trust Company, N.A.

1.35%

GSA Capital Partners LLP

1.09%

其他

89.70%

持股股东

占比

The Vanguard Group, Inc.

3.45%

Renaissance Technologies LLC

3.03%

Two Sigma Investments, LP

1.38%

BlackRock Institutional Trust Company, N.A.

1.35%

GSA Capital Partners LLP

1.09%

其他

89.70%

股东类型

持股股东

占比

Investment Advisor

8.22%

Hedge Fund

6.55%

Investment Advisor/Hedge Fund

2.89%

Research Firm

1.04%

Corporation

0.97%

Individual Investor

0.95%

其他

79.37%

机构持股



更新时间: 10月1日周三

报告期

机构数

持股数

持股占比

持股变动

2025Q3

319

55.42M

16.47%

-39.56M

2025Q2

349

61.18M

25.54%

-60.51M

2025Q1

404

58.78M

24.86%

-65.68M

2024Q4

408

67.57M

32.39%

-54.70M

2024Q3

411

61.90M

29.72%

-75.37M

2024Q2

422

105.29M

52.02%

-52.38M

2024Q1

424

122.66M

61.96%

-20.13M

2023Q4

430

104.60M

58.76%

-36.84M

2023Q3

436

126.62M

71.56%

-23.29M

2023Q2

448

137.28M

80.06%

-15.05M

股东持股明细



名称

持股数

占比

持股变动

变动比例

公告日期

The Vanguard Group, Inc.

9.37M

3.11%

Jun 30, 2025

Renaissance Technologies LLC

6.84M

2.27%

+3.67M

+115.88%

Jun 30, 2025

Two Sigma Investments, LP

2.08M

0.69%

+397.81K

+23.60%

Jun 30, 2025

BlackRock Institutional Trust Company, N.A.

4.18M

1.38%

-371.02K

-8.16%

Jun 30, 2025

GSA Capital Partners LLP

2.25M

0.74%

+1.28M

+132.40%

Jun 30, 2025

Geode Capital Management, L.L.C.

2.33M

0.77%

+48.83K

+2.14%

Jun 30, 2025

Biogen Inc

3.25M

1.08%

-11.40M

-77.82%

Aug 14, 2024

Susquehanna International Group, LLP

773.27K

0.26%

-1.04M

-57.27%

Jun 30, 2025

Charles Schwab Investment Management, Inc.

1.28M

0.42%

+183.97K

+16.76%

Jun 30, 2025

持股ETF



更新时间: 12月2日周二

机构名称

占比

Invesco NASDAQ Future Gen 200 ETF

0.62%

iShares Neuroscience and Healthcare ETF

0.28%

Global X Genomics & Biotechnology ETF

0.2%

Invesco RAFI US 1500 Small-Mid ETF

0.02%

iShares Micro-Cap ETF

ProShares Hedge Replication ETF

Schwab U.S. Small-Cap ETF

State Street SPDR S&P Kensho New Econ Comp ETF

State Street SPDR S&P Biotech ETF

Global X Russell 2000 Covered Call ETF

Invesco NASDAQ Future Gen 200 ETF

占比0.62%

iShares Neuroscience and Healthcare ETF

占比0.28%

Global X Genomics & Biotechnology ETF

占比0.2%

Invesco RAFI US 1500 Small-Mid ETF

占比0.02%

iShares Micro-Cap ETF

占比0%

ProShares Hedge Replication ETF

占比0%

Schwab U.S. Small-Cap ETF

占比0%

State Street SPDR S&P Kensho New Econ Comp ETF

占比0%

State Street SPDR S&P Biotech ETF

占比0%

Global X Russell 2000 Covered Call ETF

占比0%

分红派息



近5年累计派现 0.00 美元

公告日期

分红计划

股权登记日

现金发放日

除权除息日

暂无数据

拆合股



公告日期

类型

比率

暂无数据

公告日期

类型

比率

暂无数据

常见问题

Sangamo Therapeutics Inc的前五大股东是谁？



Sangamo Therapeutics Inc 的前五大股东如下：
The Vanguard Group, Inc.持有股份：9.37M，占总股份比例：3.11%。
Renaissance Technologies LLC持有股份：6.84M，占总股份比例：2.27%。
Two Sigma Investments, LP持有股份：2.08M，占总股份比例：0.69%。
BlackRock Institutional Trust Company, N.A.持有股份：4.18M，占总股份比例：1.38%。
GSA Capital Partners LLP持有股份：2.25M，占总股份比例：0.74%。